share_log

LifeVantage (NASDAQ:LFVN) Earns Buy Rating From Analysts at StockNews.com

Defense World ·  Aug 26, 2022 02:21

Research analysts at StockNews.com began coverage on shares of LifeVantage (NASDAQ:LFVN – Get Rating) in a report issued on Friday. The brokerage set a "buy" rating on the stock.

LifeVantage Price Performance

LifeVantage stock opened at $3.95 on Friday. LifeVantage has a 12 month low of $3.80 and a 12 month high of $8.02. The company has a fifty day moving average price of $4.30 and a two-hundred day moving average price of $4.54. The company has a market cap of $49.73 million, a PE ratio of 16.46 and a beta of 1.21.

Get LifeVantage alerts:

Hedge Funds Weigh In On LifeVantage

Hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. increased its stake in LifeVantage by 39.0% during the 4th quarter. Victory Capital Management Inc. now owns 10,633 shares of the company's stock valued at $67,000 after buying an additional 2,983 shares during the period. State Street Corp raised its holdings in LifeVantage by 7.6% during the first quarter. State Street Corp now owns 46,191 shares of the company's stock worth $220,000 after purchasing an additional 3,281 shares in the last quarter. Renaissance Technologies LLC lifted its position in LifeVantage by 0.3% in the second quarter. Renaissance Technologies LLC now owns 974,318 shares of the company's stock worth $4,238,000 after purchasing an additional 3,300 shares during the period. O Shaughnessy Asset Management LLC boosted its stake in LifeVantage by 49.8% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 23,461 shares of the company's stock valued at $148,000 after buying an additional 7,804 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of LifeVantage by 38.7% in the 4th quarter. American Century Companies Inc. now owns 35,310 shares of the company's stock worth $223,000 after purchasing an additional 9,856 shares during the last quarter. 29.54% of the stock is currently owned by institutional investors and hedge funds.

LifeVantage Company Profile

(Get Rating)

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes.

Featured Stories

  • Get a free copy of the StockNews.com research report on LifeVantage (LFVN)
  • Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
  • Is PayPal A Buy After Post-Earnings Price Jump?
  • Williams-Sonoma's High-End Consumers Are Still Spending
  • Snowflake Stock Soars On Strong Results
  • ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?

Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment